At the same time, IHC staining in transplanted tumors indicated that the CCR4 antagonist could effectively downregulate the phosphorylation of Vav2 and MLC in cancer cells, but not in tumors treated with CCL2 neutralizing antibody (Fig. 5F). Here, CCL2 is linked to cancer.